BioSyent Inc., a public company listed on the TSX Venture Exchange, has announced its plan to acquire Oral Science Inc., a Canadian distributor of dental health products based in Brossard, Quebec. The agreement was signed on February 8, and the value of the acquisition is set at $25.5 million, combining cash and shares as payment.
Under the terms of the deal, BioSyent will purchase all shares of Oral Science from its current owners. The payment consists of $22.5 million in cash and 234,192 BioSyent common shares, priced at $12.81 per share, totaling $3 million. Some of these shares will be held in escrow for two years, while others will be locked for the same period, with partial releases every six months. The purchase price covers a net working capital requirement of $6.3 million on closing.
In addition to the initial payment, the sellers will be entitled to a potential earn-out payment in 2027 based on the performance of Oral Science in 2025 and 2026. There are also contingent royalty payments, which could reach up to $6.0 million by 2033, based on sales of a specific product. The transaction is expected to be finalized before the end of February 2026, once requirements such as regulatory approvals and other conditions are met.
Oral Science was founded in Canada in 2003 and has established itself as an innovative company in the dental sector. It works with dental practices to support treatment for periodontal and endodontic diseases, high-risk cavities, dry mouth, and oral lesions. The company uses advanced healthcare technologies and follows an integrated approach focusing on diagnosis, office treatments, home-care solutions, and educational support for clinicians and patients.
Today, Oral Science’s sales are split between proprietary products and exclusive distribution agreements with international partners. About one-third of its revenue comes from its own products and technologies, while two-thirds are generated through its distribution partnerships. This acquisition is expected to strengthen BioSyent’s presence in the dental products sector, giving it access to a diversified sales model and an expanded product portfolio.